China's Generic Drug Market Still Competitive Despite Government Efforts To Promote Innovation
This article was originally published in PharmAsia News
Chinese generic drugs are still fiercely competitive despite endeavors by China's State FDA in recent years to reduce the emphasis on generic drugs in the domestic pharmaceutical market, a Shanghai Brilliance Credit Rating & Investors Service analyst remarked
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.